Literature DB >> 18650420

Paclitaxel binding to human and murine MD-2.

Shanta M Zimmer1, Jin Liu, Jaime L Clayton, David S Stephens, James P Snyder.   

Abstract

Paclitaxel (PTX) is an important cancer chemotherapeutic agent that binds to beta-tubulin and prevents mitosis through microtubule overstabilization. Recent evidence also implicates PTX in the induction of apoptosis of cancer cells via the TLR4 innate immune pathway. The TLR4 accessory protein, MD-2, is an essential component for the species-specific proinflammatory activity of PTX on murine cells. However, whether PTX binds to human MD-2 and how MD-2 and TLR4 interact with PTX are not well defined. Recombinant human MD-2 (rhMD-2) was produced in a Pichia pastoris expression system, and the interaction between rhMD-2 and PTX was assessed by an enzyme-linked immunosorbent assay to show that PTX binds rhMD-2. Formation of the latter complex was found to be dose-dependent and inhibited by anti-MD-2 antibody but not by an isotype control antibody. As measured by human tumor necrosis factor alpha production, human THP-1 monocytes expressing TLR4 and MD-2 were poorly responsive to the addition of PTX, but murine macrophages expressing TLR4 and MD-2 responded in a dose-dependent manner. Human embryonic kidney (HEK293) cells transfected with both human TLR4 and human MD-2 or human MD-2 and murine TLR4 were also poorly responsive to PTX (10 microm). However, HEK293 cells transfected with murine MD-2 and human TLR4 or murine MD-2 and murine TLR4 were highly responsive to PTX (10 microm), indicating that the murine MD-2/PTX interaction is required for TLR4 activation. To further define the structural differences for MD-2/TLR4 activation, crystal structures of both murine and human MD-2 were subjected to PTX docking by computational methods. These models indicate that PTX binds in the pocket of both human and mouse MD-2 structures. The species-specific difference between human and murine MD-2 activation of TLR4 by PTX can be explained by alterations of surface charge distribution (i.e. electrostatic potential), binding pocket size, and the locus of PTX binding within the MD-2 pocket, which results in reorganization of the 123-130 amino acid loop. In particular, Phe(126) appears to operate as a bridge for TLR4.MD-2 dimerization in the mouse but not the human protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650420      PMCID: PMC2562052          DOI: 10.1074/jbc.M802826200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  pEF-BOS, a powerful mammalian expression vector.

Authors:  S Mizushima; S Nagata
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis.

Authors:  D W Cleveland; S G Fischer; M W Kirschner; U K Laemmli
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

4.  Isolation and characterization of eight lipid A precursors from a 3-deoxy-D-manno-octylosonic acid-deficient mutant of Salmonella typhimurium.

Authors:  C R Raetz; S Purcell; M V Meyer; N Qureshi; K Takayama
Journal:  J Biol Chem       Date:  1985-12-25       Impact factor: 5.157

5.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

Authors:  M C Wani; H L Taylor; M E Wall; P Coggon; A T McPhail
Journal:  J Am Chem Soc       Date:  1971-05-05       Impact factor: 15.419

6.  Taxol: mechanisms of action and resistance.

Authors:  S B Horwitz; L Lothstein; J J Manfredi; W Mellado; J Parness; S N Roy; P B Schiff; L Sorbara; R Zeheb
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

7.  Promotion of microtubule assembly in vitro by taxol.

Authors:  P B Schiff; J Fant; S B Horwitz
Journal:  Nature       Date:  1979-02-22       Impact factor: 49.962

8.  Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway.

Authors:  Susu M Zughaier; Yih-Ling Tzeng; Shanta M Zimmer; Anup Datta; Russell W Carlson; David S Stephens
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs.

Authors:  Thota Ganesh; Rebecca C Guza; Susan Bane; Rudravajhala Ravindra; Natasha Shanker; Ami S Lakdawala; James P Snyder; David G I Kingston
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-28       Impact factor: 11.205

10.  Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations.

Authors:  Theresa L Gioannini; Athmane Teghanemt; DeSheng Zhang; Nathan P Coussens; Wendie Dockstader; S Ramaswamy; Jerrold P Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

View more
  38 in total

1.  Toll-like receptor (TLR)-4 mediates anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells.

Authors:  H Zhou; Y Yan; G Xu; B Zhou; H Wen; D Guo; F Zhou; H Wang
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

Review 2.  Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis.

Authors:  David S Stephens
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

3.  Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.

Authors:  Bahareh Kashani; Zahra Zandi; Mohammad Reza Karimzadeh; Davood Bashash; Ali Nasrollahzadeh; Seyed H Ghaffari
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

4.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Lijing Su; Murali M R P Surakattula; Michael Berger; Hua Huang; Elliot K Beutler; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2016-04-25       Impact factor: 7.446

5.  Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.

Authors:  Pankajini Mallick; Sumit Basu; Bhagavtula Moorthy; Romi Ghose
Journal:  Toxicol In Vitro       Date:  2017-02-27       Impact factor: 3.500

6.  The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.

Authors:  Yan Li; Pavel Adamek; Haijun Zhang; Claudio Esteves Tatsui; Laurence D Rhines; Petra Mrozkova; Qin Li; Alyssa K Kosturakis; Ryan M Cassidy; Daniel S Harrison; Juan P Cata; Kenneth Sapire; Hongmei Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Andre Ghetti; Jiusheng Yan; Jiri Palecek; Patrick M Dougherty
Journal:  J Neurosci       Date:  2015-09-30       Impact factor: 6.167

7.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

8.  Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Hongmei Zhang; Yan Li; Marianna de Carvalho-Barbosa; Annemieke Kavelaars; Cobi J Heijnen; Phillip J Albrecht; Patrick M Dougherty
Journal:  J Pain       Date:  2016-03-12       Impact factor: 5.820

9.  Paclitaxel ameliorates lipopolysaccharide-induced kidney injury by binding myeloid differentiation protein-2 to block Toll-like receptor 4-mediated nuclear factor-κB activation and cytokine production.

Authors:  Dongshan Zhang; Yijian Li; Yu Liu; Xudong Xiang; Zheng Dong
Journal:  J Pharmacol Exp Ther       Date:  2013-01-14       Impact factor: 4.030

10.  Potent anti-inflammatory activity of novel microtubule-modulating brominated noscapine analogs.

Authors:  Susu Zughaier; Prasanthi Karna; David Stephens; Ritu Aneja
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.